Objective:

To provide updated pooled estimates of the prevalence and malignancy risk of prostatic incidental uptake (PIU) identified on [18F]FDG PET/CT and PET/CT scans using radiotracers other than [18F]FDG.

Approach:

Key Findings:

• The pooled prevalence of PIU was 1.7% for [18F]FDG PET/CT and 4.5% for SSA PET/CT.
• The pooled malignancy rates among PIU cases that underwent further evaluation or biopsy were 21.3% and 59.7%, respectively.
• Malignant PIUs showed a higher mean age and higher mean SUVmax compared to benign PIUs.
• A peripheral location of PIU emerged as a predictor of malignancy.

Interpretation:

PIU is detected in approximately 1.7% of [18F]FDG PET/CT scans in men and is associated with a relevant risk of malignancy.

Limitations:

• The study is limited by the variability in study designs and methodologies among the included studies.
• Only original articles were included, potentially excluding relevant data from reviews or other formats.

Conclusion:

PIU should prompt individualized clinical correlation, particularly when uptake is focal, peripherally located, or associated with elevated PSA or other suspicious prostate-directed findings.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.